Quarterly report pursuant to Section 13 or 15(d)

Stockholders' Equity

v3.7.0.1
Stockholders' Equity
6 Months Ended
Jun. 30, 2017
Stockholders' Equity [Abstract]  
Stockholders' Equity

Note 6 - Stockholders’ Equity

 

Stock Options

 

The Company has an incentive stock plan, the Amended and Restated 2011 Equity Incentive Plan (the “2011 Plan”), and has granted stock options to employees, non-employee directors and consultants from the 2011 Plan. Options granted under the 2011 Plan may be Incentive Stock Options or Non-statutory Stock Options, as determined by the Administrator at the time of grant. The rules of the TSX-Venture Exchange (or “TSX-V”) provide that the maximum number of shares which can be reserved under a stock option plan is equal to 20% of the number of shares of the issuer which are outstanding on the date the plan is approved by stockholders. On June 15, 2017 the Company’s stockholders approved an amendment to the 2011 Plan to increase the number of shares authorized for issuance under the 2011 Plan to a total of 7,171,540, which is equal to 20% of the number of shares of the Company’s common stock outstanding on the date of the amendment.

 

In January 2016 the Company issued a warrant to purchase 125,000 shares of the Company’s common stock to an investor relations firm as partial compensation for consulting services it would provide the Company over a two year period. Pursuant to applicable policies of the TSX-V, the shares issuable under the warrant will be counted against the limit of shares authorized for issuance under the 2011 Plan, notwithstanding that the warrant was not issued under the 2011 Plan. After giving effect to this limitation there were 1,506,793 shares remaining available for issuance under the 2011 Plan at June 30, 2017.

 

During the six months ended June 30, 2017, the Company granted stock options to employees to purchase 1,031,000 shares of the Company’s common stock at an exercise price of $2.40 per share. The options have terms of ten years. Of the 1,031,000 stock options granted, 300,000 are subject to vesting based on continuous service over periods between zero and four years from the date of grant. The balance of the grant, or 731,000 shares, has performance-based vesting conditions and will be valued at the time the milestones are reached. The stock options have an aggregate grant date fair value of $528,580. Subsequent to the issuance, the Company cancelled 105,000 stock options during the six months ended June 30, 2017.

 

In February 2017, 16,250 stock options were exercised for cash proceeds of $19,825 and the Company cancelled 48,750 stock options.

 

The Company recorded stock based compensation as follows:

 

    For the Three Months Ended
June 30,
    For Six Months Ended
June 30,
 
    2017     2016     2017     2016  
Research and development   $ 76,267     $ 103,537     $ 142,960     $ 174,744  
General and administrative     122,184       106,118       470,004       158,557  
  Total   $ 198,451     $ 209,655     $ 612,964     $ 333,301  

 

The following table represents stock option activity for the six months ended June 30, 2017:

 

                Weighted Average        
    Stock Options     Exercise Price     Fair Value     Contractual     Aggregate  
    Outstanding     Exercisable     Outstanding     Exercisable     Vested     Life (Years)     Intrinsic Value  
Balance – December 31, 2016     4,652,497       1,908,883     $ 0.92     $ 0.41     $ 0.41       8.24     $ -  
Granted     1,031,000       100,000       2.40       2.40       6.25       6.25       -  
Exercised     (16,250 )     -       -       -       -       -       -  
Cancelled     (153,750 )     -       -       -       -       -       -  
Balance – June 30, 2017     5,513,497       2,745,159     $ 0.98     $ 0.59     $ 0.59       6.73     $ 3,805,494  

  

The following table summarizes information on stock options outstanding and exercisable as of June 30, 2017:

 

            Weighted   Weighted           Weighted  
Exercise     Number     Average Remaining   Average     Number     Average  
Price     Outstanding     Contractual Term   Exercise Price     Exercisable     Exercise Price  
                               
$ 0.05       72,876     4.76 years   $ 0.05       72,876     $ 0.05  
$ 0.26       1,024,810     6.78 years   $ 0.26       978,507     $ 0.26  
$ 0.73       1,475,687     7.38 years   $ 0.73       953,048     $ 0.73  
$ 1.00       313,124     8.06 years   $ 1.00       166,457     $ 1.00  
$ 1.10       10,000     8.53 years   $ 1.10       3,959     $ 1.10  
$ 1.17       70,000     8.37 years   $ 1.17       31,875     $ 1.17  
$ 1.22       125,000     8.60 years   $ 1.22       44,271     $ 1.22  
$ 1.50       40,000     8.67 years   $ 1.50       13,333     $ 1.50  
$ 1.55       1,456,000     8.69 years   $ 1.55       353,750     $ 1.55  
$ 2.40       926,000     9.59 years   $ 2.40       127,083     $ 2.40  
Totals       5,513,497                   2,745,159          

 

Warrants

 

In January 2017, a total of 926,588 common stock purchase warrants were exercised for aggregate cash proceeds of $1,853,176. Additional proceeds in the amount of $522,326 were received in January 2017 from warrants exercised in December 2016. During the six months ended June 30, 2017, 4,695,846 unexercised warrants expired.

 

In January and February 2017, consultants to the Company exercised a total of 106,982 warrants for aggregate cash proceeds of $29,491.

 

As of June 30, 2017, the Company had 951,635 warrants outstanding and exercisable to purchase common stock. Such warrants have a weighted average exercise price of $0.39, a weighted average remaining contractual life of 6.01 years and an aggregate intrinsic value of $1,291,950.